埃科纳佐尔局部凝的开发和表征
Mohammad F Bayan1, Balakumar Chandrasekaran1, Mohammad H Alyami2
1Faculty of Pharmacy, Philadelphia University, P.O. Box 1, Amman 19392, Jordan.
Gels (Basel, Switzerland)
|December 22, 2023
概括
这项研究开发了一种用于治疗真菌感染的新型econazole酸盐凝配方. 优化的凝表现出有效的抗真菌活性和受控的药物释放,提供了一个有前途的局部治疗选择.
科学领域:
- 制药科学 制药科学
- 皮肤病学 皮肤病学
- 菌类学 菌类学是指菌类学.
背景情况:
- 埃科纳酸盐是一种局部抗真菌剂,用于各种真菌和酵母菌感染.
- 局部凝比乳和药膏具有优势,包括更快的药物释放.
- 开发可扩展的,单一的局部配方对于有效的治疗提供至关重要.
研究的目的:
- 开发一种新的,可扩展的,单局部凝配方的econazole酸盐.
- 描述开发的生化酸盐凝的物理,化学和抗真菌特性.
- 为了研究在体外释放药物的行为和机制的econazole酸盐凝.
主要方法:
- 使用Carbopol® 940,乙烯甘醇,Capmul® MCM C8和类来制备生态酸盐凝.
- 物理性质的评估:外观,均性,pH值,粘度,可扩散性和凝强度.
- 使用杯盘扩散方法对Candida albicans和Aspergillus fumigatus的抗真菌活性进行评估.
- 在体外释放研究和动力学分析使用Korsmeyer-Peppas模型.
主要成果:
- 开发的econazole酸盐凝是透明的,淡黄色的,均的,pH值约为6.0.
- 增加Carbopol® 940度增加了粘度和凝强度,但减少了扩散性.
- 配方对Candida albicans和Aspergillus fumigatus表现出显著的抗真菌活性.
- 在体外释放研究表明,较高的Carbopol® 940度降低了药物释放.
- 科尔斯迈耶-佩帕斯模型表明,药物释放通过扩散和凝胀 (n > 0.5 和 < 1) 控制.
结论:
- 成功开发了一种新的,可扩展的,单性埃科纳酸盐凝配方.
- 优化的凝具有合适的物理化学特性,并表现出强大的抗真菌活性.
- 该配方的药物释放机制是由扩散和胀控制的,这表明持续局部抗真菌治疗的潜力.
相关概念视频
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...